Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.66 and traded as high as $4.41. Cumberland Pharmaceuticals shares last traded at $4.36, with a volume of 33,426 shares traded.
Wall Street Analysts Forecast Growth
Separately, StockNews.com upgraded Cumberland Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday, March 6th.
Check Out Our Latest Analysis on Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Stock Down 1.6 %
The company has a current ratio of 1.13, a quick ratio of 0.99 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $59.08 million, a PE ratio of -5.49 and a beta of -0.24. The stock's fifty day simple moving average is $4.68 and its 200-day simple moving average is $2.71.
Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last issued its quarterly earnings results on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%. The business had revenue of $10.44 million for the quarter.
Institutional Trading of Cumberland Pharmaceuticals
An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Two Sigma Investments LP increased its stake in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Free Report) by 94.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 37,649 shares of the specialty pharmaceutical company's stock after purchasing an additional 18,271 shares during the quarter. Two Sigma Investments LP owned approximately 0.27% of Cumberland Pharmaceuticals worth $89,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 15.51% of the company's stock.
About Cumberland Pharmaceuticals
(
Get Free Report)
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
See Also
Before you consider Cumberland Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cumberland Pharmaceuticals wasn't on the list.
While Cumberland Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
